The Contribution of Drugs and Helicobacter pylori to Gastric Mucosa Changes in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome

Abstract EN

Background.

The nature and rate of gastric mucosal (GM) damage in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) remain to be among the unsolved problems.

Objective.

To define the role of H.

pylori and drugs in the development of GM damages in SLE and APS.

Methods.

A study was conducted on 85 patients with SLE and APS.

All the patients underwent esophagogastroduodenoscopy with targeted biopsy of the mucosa of the gastric body and antrum.

The presence of H.

pylori in the gastric biopsy specimens was determined using polymerase chain reaction.

Results.

Endoscopic examination revealed that the patients with SLE and APS on admission had the following GM changes: antral gastritis (82.4%), erosions (24.7%), hemorrhages (8.2%), and pangastritis (8.2%).

SLE and APS patients showed no direct correlation between the found GM damages and the presence of H.

pylori.

The use of glucocorticoid, low-dose acetylsalicylic acid, nonsteroidal anti-inflammatory drug, and anticoagulant in SLE and APS patients is accompanied by GM damage.

Conclusion.

There was no evidence of the role of H.

pylori in GM damage in the SLE and APS patients.

More frequent detection of H.

pylori was observed in anticoagulants or low-dose acetylsalicylic acid users than in glucocorticoids and nonsteroidal anti-inflammatory drugs ones.